Published in Ann Rheum Dis on April 05, 2004
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther (2005) 1.58
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther (2006) 1.17
New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol (2009) 0.91
Etanercept and venous thromboembolism: a case series. J Med Case Rep (2010) 0.89
Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol (2014) 0.85
Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 0.81
Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med (2014) 0.80
Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report. Med Sci Monit (2014) 0.78
Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag (2007) 0.78
The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag (2007) 0.76
Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int Arch Med (2012) 0.75
Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra. Case Rep Rheumatol (2016) 0.75
Acute renal artery occlusion following infliximab infusion. World J Nephrol (2013) 0.75
Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Rep Rheumatol (2014) 0.75
Permanent renal loss following tumor necrosis factor α antagonists for arthritis. Rheumatol Int (2009) 0.75
Adalimumab therapy--a double-edged sword? Int J Colorectal Dis (2011) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol (1983) 8.37
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol (1993) 4.62
Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol (1989) 3.00
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 2.96
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum (2002) 1.48
Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med (1997) 1.41
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum (2003) 1.41
Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med (1990) 1.13
Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis (2002) 1.10
Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol (1994) 0.94
Anticardiolipin antibodies in rheumatoid arthritis. Br J Rheumatol (1987) 0.92
The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol (1989) 0.92
Anticardiolipin antibodies in patients with venous thrombosis. Haemostasis (1991) 0.91
B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum (2002) 0.88
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis (2003) 4.36
Epidermal Langerhans cells express Ia antigens. Nature (1977) 3.51
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis (2003) 3.43
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis (2008) 3.42
Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods (1988) 2.84
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis (2005) 2.62
Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum (1986) 2.56
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ (1998) 2.51
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med (2010) 2.30
Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27
Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Appearance of anti-HLA-DR-reactive cells in normal and rheumatoid synovial tissue. Scand J Immunol (1981) 2.02
Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci U S A (1982) 1.99
T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol (1985) 1.96
Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis (2005) 1.96
Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum (1989) 1.95
Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis (2006) 1.93
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis (2010) 1.90
Hormonal regulation of the expression of Ia antigens on mammary gland epithelium. Eur J Immunol (1980) 1.90
Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum (1986) 1.90
Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin Exp Immunol (1985) 1.89
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis (2005) 1.85
Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. Arthritis Rheum (1983) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Occurrence of Ia antigens on tissues on non-lymphoid origin. Nature (1978) 1.76
Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol (2001) 1.72
Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis (2008) 1.71
Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis (1995) 1.71
In situ identification of T lymphocyte subsets and HLA-DR expressing cells in the human skin tuberculin reaction. Clin Exp Immunol (1982) 1.71
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis (2008) 1.69
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens. Rheumatology (Oxford) (2001) 1.66
Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol (2010) 1.65
Evolutionary relationship between immunoglobulins and transplantation antigens. Proc Natl Acad Sci U S A (1975) 1.62
Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol (1983) 1.58
Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. J Autoimmun (1991) 1.57
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis (2004) 1.56
The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol (1981) 1.53
Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis (2000) 1.53
CTL response to Mycobacterium tuberculosis: identification of an immunogenic epitope in the 19-kDa lipoprotein. J Immunol (1998) 1.52
When to initiate and discontinue biologic treatments for rheumatoid arthritis? J Intern Med (2011) 1.50
Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis (2008) 1.49
High antibody response to autologous type II collagen is restricted to H-2q. Immunogenetics (1986) 1.49
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum (2000) 1.49
Relationship between HLA-DR-expressing cells and T lymphocytes of different subsets in rheumatoid synovial tissue. Scand J Immunol (1981) 1.48
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis (2003) 1.48
Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet (1988) 1.46
The effect of female sex hormones on cancer survival. A register-based study in patients younger than 20 years at diagnosis. JAMA (1990) 1.45
Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum (1997) 1.45
Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum (1994) 1.44
Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum (1988) 1.44
Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) (2002) 1.41
Chemical properties of human Ia antigens. Nature (1977) 1.40
Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum (2004) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis (2004) 1.32
Distribution of Ia-antigen-like molecules on non-lymphoid tissues. Scand J Immunol (1979) 1.32
Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis (2005) 1.32
Early appearance of activated CD4+ T lymphocytes and class II antigen-expressing cells in joints of DBA/1 mice immunized with type II collagen. Lab Invest (1988) 1.32
European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis (2008) 1.31
Phenotypic characterization in situ of inflammatory cells in allergic and irritant contact dermatitis in man. Clin Exp Immunol (1984) 1.29
Immune functions of human synovial cells. Phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum (1982) 1.29
Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjögren's syndrome. Clin Exp Immunol (1985) 1.27
Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol (2005) 1.27
Presence of human 65 kD heat shock protein (hsp) in inflamed joints and subcutaneous nodules of RA patients. Scand J Immunol (1990) 1.27
A demineralization procedure for immunohistopathological use. EDTA treatment preserves lymphoid cell surface antigens. J Immunol Methods (1986) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol (1997) 1.24
Role of T lymphocytes in murine collagen induced arthritis. Agents Actions (1986) 1.24
Heavy HLA-DR (Ia) antigen chain is controlled by the MHC region. Nature (1978) 1.24
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis (2001) 1.24
Homologous type II collagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum (1990) 1.23
Reactivity of a rabbit antiserum against highly purified HLA-DR antigens. Scand J Immunol (1978) 1.21
In vivo treatment of rats with monoclonal anti-T-cell antibodies. Immunohistochemical and functional analysis in normal rats and in experimental allergic neuritis. Scand J Immunol (1985) 1.20
Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol (1995) 1.19
Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin Exp Immunol (1999) 1.18
Sialadenitis in the MRL-l mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology (1987) 1.17
Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis (2001) 1.16
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis (2007) 1.16
FOXP3 identifies regulatory CD25bright CD4+ T cells in rheumatic joints. Scand J Immunol (2006) 1.15